When a man is diagnosed with aggressive prostate cancer and surgery is on the table, a big question is: what's the real extent of the disease? A large international study of 775 men found that a specialized PET/CT scan using a tracer called Ga-PSMA-11 could provide a clearer picture. The scan results, which showed whether cancer had spread to lymph nodes or beyond, were strongly linked to what happened next.
Men whose scans showed no spread (N0M0) had the best outcomes, with about 57% surviving two years without their cancer progressing. Those with spread to lymph nodes (N1M0) had a tougher road, and men whose scans revealed distant metastases (NxM1) faced the most significant challenge, with only about 26% event-free at two years and a notably lower overall survival rate of 87%.
It's important to understand what this study shows and what it doesn't. The scan results were a powerful prognostic sign—a marker of what was likely to happen. But this was an observational study; it didn't compare the scan to standard staging methods, so we can't say for sure if using it actually leads to better survival. The findings are a promising step toward more personalized treatment planning, showing that the scan's snapshot of the disease is deeply connected to a patient's journey.